CIK 0000818686 · Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- Phone
- 972 (3) 914-8213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,923,078
- in 11 filings, $11.2M under 10b5-1 plans
Net −$33,923,078. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-15 | Francis Richard D President and CEO | Option exercise · Restricted Share Units 10b5-1 | −161,656 | 0 | ||
| 2026-02-15 | Francis Richard D President and CEO | Option exercise · Restricted Share Units 10b5-1 | −620,110 | 0 | ||
| 2026-01-27 | Kalif Eliyahu Sharon EVP, Chief Financial Officer | Grant or award · Restricted Share Units | +141,478 | 141,478 | ||
| 2026-01-27 | Hughes Eric A See "Remarks" | Grant or award · Restricted Share Units | +141,478 | 141,478 | ||
| 2026-01-27 | Sabag Mark See "Remarks" | Grant or award · Restricted Share Units | +141,478 | 141,478 | ||
| 2026-01-27 | Daniell Richard Exec. VP, European Commercial | Grant or award · Restricted Share Units | +141,478 | 141,478 | ||
| 2026-01-27 | Francis Richard D President and CEO | Grant or award · Restricted Share Units | +620,110 | 620,110 | ||
| 2026-01-27 | Francis Richard D President and CEO | Grant or award · Restricted Share Units | +891,315 | 891,315 | ||
| 2025-12-16 | Weiss Amir Chief Accounting Officer | Sale | −12,300 | $30.20 | $372K | 5,650 |
| 2025-12-16 | MIGNONE ROBERTO Director | Sale | −77,400 | $30.24 | $2.3M | 367,600 |
| 2025-12-09 | Daniell Richard Exec. VP, European Commercial | Option exercise | +100,457 | $18.61 | $1.9M | 148,841 |
| 2025-12-09 | Daniell Richard Exec. VP, European Commercial | Option exercise | +15,011 | $16.99 | $255K | 163,852 |
| 2025-12-09 | Daniell Richard Exec. VP, European Commercial | Sale | −115,468 | $28.68 | $3.3M | 48,384 |
| 2025-12-09 | Daniell Richard Exec. VP, European Commercial | Option exercise · Stock Options (right to buy) | −100,457 | 0 | ||
| 2025-12-09 | Daniell Richard Exec. VP, European Commercial | Option exercise · Stock Options (right to buy) | −15,011 | 0 | ||
| 2025-12-09 | Sabag Mark See "Remarks" | Option exercise | +118,724 | $18.61 | $2.2M | 269,720 |
| 2025-12-09 | Sabag Mark See "Remarks" | Sale | −118,724 | $28.75 | $3.4M | 150,996 |
| 2025-12-09 | Sabag Mark See "Remarks" | Sale | −98,168 | $28.70 | $2.8M | 52,828 |
| 2025-12-09 | Sabag Mark See "Remarks" | Option exercise · Stock Options (right to buy) | −118,724 | 0 | ||
| 2025-12-02 | Lichtenstein Chen Director | Option exercise | +4,804 | 4,804 |
Page 11 of 76 · 1,517 trades